Cullinan Associates Inc. Purchases 6,900 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Share on StockTwits

Cullinan Associates Inc. lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 153.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 11,400 shares of the biopharmaceutical company’s stock after acquiring an additional 6,900 shares during the quarter. Cullinan Associates Inc.’s holdings in Gilead Sciences were worth $741,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. LeJeune Puetz Investment Counsel LLC raised its holdings in shares of Gilead Sciences by 0.6% in the 3rd quarter. LeJeune Puetz Investment Counsel LLC now owns 26,385 shares of the biopharmaceutical company’s stock valued at $1,672,000 after acquiring an additional 155 shares in the last quarter. Cornerstone Wealth Management LLC raised its holdings in shares of Gilead Sciences by 3.6% in the 3rd quarter. Cornerstone Wealth Management LLC now owns 4,962 shares of the biopharmaceutical company’s stock valued at $314,000 after acquiring an additional 174 shares in the last quarter. Unison Advisors LLC raised its holdings in shares of Gilead Sciences by 1.0% in the 4th quarter. Unison Advisors LLC now owns 18,342 shares of the biopharmaceutical company’s stock valued at $1,192,000 after acquiring an additional 177 shares in the last quarter. Municipal Employees Retirement System of Michigan raised its holdings in shares of Gilead Sciences by 0.5% in the 3rd quarter. Municipal Employees Retirement System of Michigan now owns 33,530 shares of the biopharmaceutical company’s stock valued at $2,125,000 after acquiring an additional 180 shares in the last quarter. Finally, Larson Financial Group LLC raised its holdings in shares of Gilead Sciences by 30.7% in the 3rd quarter. Larson Financial Group LLC now owns 826 shares of the biopharmaceutical company’s stock valued at $52,000 after acquiring an additional 194 shares in the last quarter. Institutional investors own 79.28% of the company’s stock.

Shares of NASDAQ GILD opened at $64.10 on Thursday. The stock has a market cap of $81.22 billion, a price-to-earnings ratio of 10.42, a P/E/G ratio of 3.90 and a beta of 1.11. The company has a current ratio of 2.96, a quick ratio of 2.87 and a debt-to-equity ratio of 1.11. Gilead Sciences, Inc. has a 1-year low of $60.89 and a 1-year high of $70.50. The stock’s 50-day moving average is $66.05 and its 200 day moving average is $65.25.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 24th. The biopharmaceutical company reported $1.75 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.74 by $0.01. Gilead Sciences had a return on equity of 37.50% and a net margin of 12.04%. The company had revenue of $5.60 billion for the quarter, compared to analysts’ expectations of $5.61 billion. During the same period last year, the firm posted $1.84 EPS. Gilead Sciences’s revenue for the quarter was up .1% compared to the same quarter last year. On average, analysts forecast that Gilead Sciences, Inc. will post 6.63 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were given a dividend of $0.63 per share. The ex-dividend date was Thursday, December 12th. This represents a $2.52 annualized dividend and a yield of 3.93%. Gilead Sciences’s payout ratio is 40.98%.

In related news, EVP Brett A. Pletcher sold 2,950 shares of the firm’s stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $64.63, for a total transaction of $190,658.50. Following the transaction, the executive vice president now directly owns 20,014 shares in the company, valued at approximately $1,293,504.82. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Brett A. Pletcher sold 5,677 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $63.31, for a total value of $359,410.87. Following the transaction, the executive vice president now owns 21,521 shares in the company, valued at $1,362,494.51. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 45,622 shares of company stock worth $2,986,438. 0.20% of the stock is owned by corporate insiders.

Several analysts have weighed in on GILD shares. ValuEngine raised Gilead Sciences from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. BidaskClub cut Gilead Sciences from a “sell” rating to a “strong sell” rating in a report on Wednesday. Maxim Group cut Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, October 25th. Cantor Fitzgerald decreased their price objective on Gilead Sciences from $88.00 to $85.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. Finally, SunTrust Banks began coverage on Gilead Sciences in a report on Tuesday, November 12th. They set a “hold” rating and a $70.00 price objective on the stock. Three analysts have rated the stock with a sell rating, nine have issued a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. Gilead Sciences presently has an average rating of “Hold” and an average target price of $78.91.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Read More: Cash Flow

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.